Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia G Synnott

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Health Policy OPEN|June 29, 2023
The impact of external reference pricing on pharmaceutical costs and market dynamicsDominic Voehler, Benjamin C Koethe, Patricia G Synnott, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 15, 2025
Characterizing financial risk from out-of-pocket expenditures across dementia stagesPatricia G Synnott, Yingying Zhu, Angie Mae Rodday, et al.
BMJ Global Health|June 8, 2021
Bridging the gap: aligning economic research with disease burdenLauren A Do, Patricia G Synnott, Siyu Ma, et al.
Applied Health Economics and Health Policy|December 18, 2022
The Value of New: Consideration of Product Novelty in Health Technology Assessments of PharmaceuticalsPatricia G Synnott, Dominic Voehler, Daniel E Enright, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2020
The Effectiveness and Value of Siponimod for Secondary Progressive Multiple SclerosisPatricia G Synnott, Lisa M Bloudek, Ravi Sharaf, et al.
International Journal of Technology Assessment in Health Care|April 21, 2022
Is Value Portable? An Examination of Contextual and Practical Considerations that Affect the Transferability of Value Assessments between SettingsPatricia G Synnott, Pei-Jung Lin, Stacey S Hickson, et al.
Journal of Managed Care & Specialty Pharmacy|May 29, 2020
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular DiseasePatricia G Synnott, R Brett McQueen, Daniel A Ollendorf, et al.
JAMA Network Open|October 31, 2024
Modeling the Population Equity of Alzheimer Disease Treatments in the USPatricia G Synnott, Thomas Majda, Pei-Jung Lin, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
The effectiveness and value of aducanumab for Alzheimer's diseasePatricia G Synnott, Melanie D Whittington, Grace A Lin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2016
Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial FibrillationChristopher G Cameron, Patricia G Synnott, Steven D Pearson, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Health Policy OPEN|June 29, 2023
The impact of external reference pricing on pharmaceutical costs and market dynamicsDominic Voehler, Benjamin C Koethe, Patricia G Synnott, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 15, 2025
Characterizing financial risk from out-of-pocket expenditures across dementia stagesPatricia G Synnott, Yingying Zhu, Angie Mae Rodday, et al.
BMJ Global Health|June 8, 2021
Bridging the gap: aligning economic research with disease burdenLauren A Do, Patricia G Synnott, Siyu Ma, et al.
Applied Health Economics and Health Policy|December 18, 2022
The Value of New: Consideration of Product Novelty in Health Technology Assessments of PharmaceuticalsPatricia G Synnott, Dominic Voehler, Daniel E Enright, et al.
Journal of Managed Care & Specialty Pharmacy|February 28, 2020
The Effectiveness and Value of Siponimod for Secondary Progressive Multiple SclerosisPatricia G Synnott, Lisa M Bloudek, Ravi Sharaf, et al.
International Journal of Technology Assessment in Health Care|April 21, 2022
Is Value Portable? An Examination of Contextual and Practical Considerations that Affect the Transferability of Value Assessments between SettingsPatricia G Synnott, Pei-Jung Lin, Stacey S Hickson, et al.
Journal of Managed Care & Specialty Pharmacy|May 29, 2020
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular DiseasePatricia G Synnott, R Brett McQueen, Daniel A Ollendorf, et al.
JAMA Network Open|October 31, 2024
Modeling the Population Equity of Alzheimer Disease Treatments in the USPatricia G Synnott, Thomas Majda, Pei-Jung Lin, et al.
Journal of Managed Care & Specialty Pharmacy|October 29, 2021
The effectiveness and value of aducanumab for Alzheimer's diseasePatricia G Synnott, Melanie D Whittington, Grace A Lin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 28, 2016
Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial FibrillationChristopher G Cameron, Patricia G Synnott, Steven D Pearson, et al.
Pageof 3